checkAd
    Startseite > Aktien > Biodexa Pharmaceuticals > Nachrichten
    Biodexa Pharmaceuticals Aktie
    0,0655
     
    USD
    -4,52 %
    -0,0031 USD
    Letzter Kurs 03.07.23 Nasdaq
    0,0655
     
    USD
    15.000 STK
    Geldkurs 03.07.23
    0,0679
     
    USD
    67.200 STK
    Briefkurs 03.07.23
    ISIN: US59564R6099 · WKN: A3D7BE · SYM: BDRX · Großbritannien

    Neueste Nachrichten

    Preliminary Results for the Year Ended 31 December 2023
    19.04.24 · globenewswire · Biodexa Pharmaceuticals
    Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update
    23.02.24 · globenewswire · Biodexa Pharmaceuticals
    Biodexa Reports 12 Month Survival in MAGIC-G1 Study of MTX110 in Recurrent Glioblastoma Patients
    08.02.24 · globenewswire · Biodexa Pharmaceuticals
    Biodexa Announces Allowance of U.S. Patent Covering Tolimidone
    07.02.24 · globenewswire · Biodexa Pharmaceuticals
    Biodexa CEO Issues Shareholder Letter Highlighting Progress in 2023 and Expected Milestones in 2024
    22.01.24 · globenewswire · Biodexa Pharmaceuticals
    Biodexa Appoints Ann Merchant to the Board of Directors
    29.12.23 · globenewswire · Biodexa Pharmaceuticals
    Biodexa Announces Closing Of $6.0 Million Underwritten Public Offering, Including Full Exercise Of Overallotment Option
    21.12.23 · globenewswire · Biodexa Pharmaceuticals
    Biodexa Announces Pricing of $5.2 Million Underwritten Public Offering
    19.12.23 · globenewswire · Biodexa Pharmaceuticals
    Biodexa Enters Into Agreements to Acquire Exclusive Worldwide License to Tolimidone, a Phase II Ready Asset for Type 1 Diabetes
    27.11.23 · globenewswire · Biodexa Pharmaceuticals
    Biodexa Completes Recruitment of Cohort A in Study of MTX110 in Patients with Recurrent Glioblastoma
    03.10.23 · globenewswire · Biodexa Pharmaceuticals
    Interim results for the six months ended 30 June 2023
    29.09.23 · globenewswire · Biodexa Pharmaceuticals
    Biodexa to Present Recruitment and Treatment Update in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma at 2023 Annual European Association of Neuro-Oncology Meeting (EANO)
    21.09.23 · globenewswire · Biodexa Pharmaceuticals